Innate Pharma: Further clinical data for lirilumab and IPH4102 presented at Ash annual meeting

Innate Pharma: Further clinical data for lirilumab and IPH4102 presented at Ash annual meeting


Enrollment in the first-in-human trial of IPH4102 in relapsed/refractory cutaneaous T-cell lymphomas is proceeding with no dose-limiting toxicities to date; Dose level 9 out of 10 is currently enrolling; Preliminary indications of objective clinical activity have already been reported in 38% of patients across all dosage levels. Early data from the combination of lirilumab with azacytidine show a good safety profile in patients with relapsed acute myeloid leukemia .



from Biotech News